You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Baxter
Express Scripts
Colorcon
Harvard Business School

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Abemaciclib - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for abemaciclib and what is the scope of patent protection?

Abemaciclib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Abemaciclib has forty-eight patent family members in forty-three countries.

One supplier is listed for this compound.

Summary for abemaciclib
International Patents:48
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 66
Clinical Trials: 101
Patent Applications: 63
DailyMed Link:abemaciclib at DailyMed
Recent Clinical Trials for abemaciclib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 1
Apices Soluciones S.L.Phase 1
Fundacion CRIS de Investigación para Vencer el CáncerPhase 1

See all abemaciclib clinical trials

Pharmacology for abemaciclib
Drug ClassKinase Inhibitor
Mechanism of ActionKinase Inhibitors

US Patents and Regulatory Information for abemaciclib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-004 Sep 28, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-002 Sep 28, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-003 Sep 28, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-003 Sep 28, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-001 Sep 28, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-003 Sep 28, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for abemaciclib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2379528 C02379528/01 Switzerland   Start Trial PRODUCT NAME: ABEMACICLIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66833 21.05.2019
2379528 PA2019004,C2379528 Lithuania   Start Trial PRODUCT NAME: ABEMACIKLIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1307 20180927
2379528 C20190008 00271 Estonia   Start Trial PRODUCT NAME: ABEMATSIKLIIB;REG NO/DATE: EU/1/18/1307 01.10.2018
2379528 C201930017 Spain   Start Trial PRODUCT NAME: ABEMACICLIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1307; DATE OF AUTHORISATION: 20180927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1307; DATE OF FIRST AUTHORISATION IN EEA: 20180927
2379528 132019000000037 Italy   Start Trial PRODUCT NAME: ABEMACICLIB(VERZENIOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1307, 20181001
2379528 2019C/507 Belgium   Start Trial PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Boehringer Ingelheim
McKesson
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.